Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Elzonris
Generic name : Tagraxofusp
Manufactured By : Stemline
Indications : Blastic Plasmocytoid Dendritic Cell Neoplasm
Medicine Description : A CD123-targeted therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. It delivers a cytotoxic protein to cancer cells, reducing tumor burden and improving patient outcomes.
Elzonris (Tagraxofusp) is a prescription medicine used to treat adults and children aged 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer.
Elzonris is a targeted therapy that combines a diphtheria toxin with a protein that binds to CD123, a marker found on BPDCN cells. Once inside the cancer cells, the toxin disrupts protein synthesis, leading to cell death.
Elzonris is approved for adults and pediatric patients (2 years and older) who have been diagnosed with BPDCN, whether newly diagnosed or relapsed/refractory.
Elzonris is administered as an intravenous (IV) infusion, typically once daily for 5 consecutive days in a 21-day cycle. Treatment is provided in a healthcare setting under medical supervision.
Common side effects include fatigue, nausea, swelling, fever, chills, weight gain, rash, and decreased appetite.
Yes, serious side effects may include capillary leak syndrome (a potentially life-threatening condition), liver problems, low blood counts, and infusion-related reactions. Immediate medical attention is required if symptoms worsen.
Treatment duration varies based on individual response and tolerance. Doctors will monitor blood work and disease progression to determine how long treatment should continue.
It is advised to avoid alcohol during treatment, as it may increase the risk of liver-related side effects and interfere with recovery.
No, Elzonris may cause harm to an unborn baby. Patients should use effective contraception during treatment and for some time after the final dose. Breastfeeding is also not recommended.
Yes, Elzonris may interact with other drugs or therapies. Always inform your healthcare provider about all medications, supplements, or herbal products you’re using.
Since Elzonris is given in a healthcare facility, missed doses are rare. However, if a dose is missed, contact your doctor or treatment center as soon as possible.
Elzonris is not an oral medication, so food does not affect its administration. Patients should maintain a healthy diet to support overall treatment and recovery.
Stay hydrated, monitor for signs of capillary leak syndrome (sudden swelling, low blood pressure, difficulty breathing), attend all follow-up appointments, and undergo regular lab tests.
Elzonris is stored and prepared by medical professionals in a hospital or clinical setting. Patients do not need to handle the medication at home.
Elzonris is only available through specialized cancer treatment centers or hospitals with a valid prescription and administered under the supervision of a qualified medical team. Pharma Five assists in its procurement.